Umbilical cord mesenchymal stem cells for COVID ‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial

Lanzoni, G., Linetsky, E., Correa, D., Messinger Cayetano, S., Alvarez, R. A., Kouroupis, D., Alvarez Gil, A., Poggioli, R., Ruiz, P., Marttos, A. C., Hirani, K., Bell, C. A., Kusack, H., Rafkin, L., Baidal, D., Pastewski, A., Gawri, K., Leñero, C., Mantero, A. M. A., Metalonis, S. W., Wang, X., Roque, L., Masters, B., Kenyon, N. S., Ginzburg, E., Xu, X., Tan, J., Caplan, A. I., Glassberg, M. K., Alejandro, R. and Ricordi, C.  Umbilical cord mesenchymal stem cells for COVID ‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial.  STEM CELLS Translational Medicine. 2021.  doi: 10.1002/sctm.20-0472

Date

BioLife Solutions Symbol

This website uses cookies to ensure you get the best experience on our website.